Anti-Coagulants - Georgia

Georgia

The Anti-Coagulants market in Georgia is expected to experience significant revenue growth in the coming years.
By 2024, the projected revenue is estimated to reach US$3.80m.
This growth is expected to continue with an annual growth rate of 8.16% from 2024 to 2028.
As a result, the market volume is projected to reach US$5.20m by 2028.
In comparison to other countries, United States is anticipated to generate the highest revenue in the Anti-Coagulants market.
In 2024 alone, the revenue United States is expected to reach a staggering US$16,740.00m.
Georgia is experiencing a growing demand for anti-coagulants due to an aging population and increasing awareness about cardiovascular health.

Key regions: Germany, South Korea, France, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Coagulants in Georgia has been on a steady rise in the past few years.

Customer preferences: Anti-Coagulants are used to prevent blood clots that can lead to serious health issues such as stroke, heart attack, and pulmonary embolism. In Georgia, the aging population is more prone to these health issues, leading to a higher demand for Anti-Coagulants. Additionally, the prevalence of lifestyle diseases such as obesity and diabetes has also contributed to the rise in demand for Anti-Coagulants.

Trends in the market: The Anti-Coagulants market in Georgia is dominated by oral Anti-Coagulants, which are preferred over injectable Anti-Coagulants due to their ease of use. The market has seen a shift towards the use of newer oral Anti-Coagulants such as Factor Xa inhibitors, which have a lower risk of bleeding compared to traditional Anti-Coagulants. The market is also witnessing an increase in the use of combination therapy, where Anti-Coagulants are used in combination with other drugs to manage health conditions.

Local special circumstances: Georgia has a high prevalence of Hepatitis C, which increases the risk of liver disease and blood clotting. This has led to a higher demand for Anti-Coagulants in the country. Additionally, Georgia has a high burden of cardiovascular disease, which is a major driver of the Anti-Coagulants market.

Underlying macroeconomic factors: Georgia has a growing economy, which has led to an increase in healthcare spending. This has contributed to the growth of the Anti-Coagulants market in the country. However, the market is also facing challenges such as a lack of awareness among the general population about the importance of Anti-Coagulants, and the high cost of newer oral Anti-Coagulants which may not be affordable for all patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.